IL276197A - Composition and method for reducing the neutrophil deficiency caused by chemotherapy through the administration of palinabolin and G-CSF factor - Google Patents

Composition and method for reducing the neutrophil deficiency caused by chemotherapy through the administration of palinabolin and G-CSF factor

Info

Publication number
IL276197A
IL276197A IL276197A IL27619720A IL276197A IL 276197 A IL276197 A IL 276197A IL 276197 A IL276197 A IL 276197A IL 27619720 A IL27619720 A IL 27619720A IL 276197 A IL276197 A IL 276197A
Authority
IL
Israel
Prior art keywords
plinabulin
administration
composition
induced neutropenia
reducing chemotherapy
Prior art date
Application number
IL276197A
Other languages
English (en)
Hebrew (he)
Original Assignee
Beyondspring Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beyondspring Pharmaceuticals Inc filed Critical Beyondspring Pharmaceuticals Inc
Publication of IL276197A publication Critical patent/IL276197A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
IL276197A 2018-02-01 2020-07-21 Composition and method for reducing the neutrophil deficiency caused by chemotherapy through the administration of palinabolin and G-CSF factor IL276197A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862625290P 2018-02-01 2018-02-01
US201862713486P 2018-08-01 2018-08-01
US201862749060P 2018-10-22 2018-10-22
US201862757648P 2018-11-08 2018-11-08
PCT/US2019/015867 WO2019152530A1 (en) 2018-02-01 2019-01-30 Composition and method for reducing chemotherapy-induced neutropenia via the administration of plinabulin and a g-csf agent

Publications (1)

Publication Number Publication Date
IL276197A true IL276197A (en) 2020-09-30

Family

ID=67479904

Family Applications (1)

Application Number Title Priority Date Filing Date
IL276197A IL276197A (en) 2018-02-01 2020-07-21 Composition and method for reducing the neutrophil deficiency caused by chemotherapy through the administration of palinabolin and G-CSF factor

Country Status (11)

Country Link
US (1) US20210030843A1 (enrdf_load_stackoverflow)
EP (1) EP3746076A4 (enrdf_load_stackoverflow)
JP (2) JP2021512121A (enrdf_load_stackoverflow)
KR (1) KR20200116477A (enrdf_load_stackoverflow)
CN (1) CN112105363A (enrdf_load_stackoverflow)
AU (1) AU2019216305B2 (enrdf_load_stackoverflow)
BR (1) BR112020015758A2 (enrdf_load_stackoverflow)
CA (1) CA3089391A1 (enrdf_load_stackoverflow)
IL (1) IL276197A (enrdf_load_stackoverflow)
SG (1) SG11202006990TA (enrdf_load_stackoverflow)
WO (1) WO2019152530A1 (enrdf_load_stackoverflow)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10202008673WA (en) 2015-03-06 2020-10-29 Beyondspring Pharmaceuticals Inc Method of treating cancer associated with a ras mutation
EP3334726B1 (en) 2015-07-13 2022-03-16 Beyondspring Pharmaceuticals, Inc. Plinabulin compositions
NZ744854A (en) 2016-02-08 2020-01-31 Beyondspring Pharmaceuticals Inc Compositions containing tucaresol or its analogs
AU2017278245B2 (en) 2016-06-06 2022-09-15 Beyondspring Pharmaceuticals, Inc. Composition and method for reducing neutropenia
JP2020503363A (ja) 2017-01-06 2020-01-30 ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド チューブリン結合化合物およびその治療的使用
KR20190109479A (ko) 2017-02-01 2019-09-25 비욘드스프링 파마수티컬스, 인코포레이티드. 호중구감소증의 감소 방법
JP7350015B2 (ja) 2018-01-24 2023-09-25 ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド プリナブリンの投与による血小板減少症を軽減するための組成物および方法
US11684655B2 (en) 2019-05-31 2023-06-27 Spectrum Pharmaceuticals, Inc. Methods of treating neutorpenia using G-CSF protein complex
US11267858B2 (en) 2019-05-31 2022-03-08 Spectrum Pharmaceuticals, Inc. Methods of treatment using G-CSF protein complex
JP2022552011A (ja) * 2019-10-15 2022-12-14 ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド 鉄障害を処置するための方法及び組成物
CA3160599A1 (en) * 2019-12-05 2021-06-10 Jae Hyuk Choi Methods of treating chemotherapy or radiotherapy induced neutropenia
WO2022015710A1 (en) * 2020-07-17 2022-01-20 Spectrum Pharmaceuticals, Inc. Methods of treating chemotherapy induced neutropenia using fixed doses of g-csf protein complex
WO2022133492A1 (en) * 2020-12-18 2022-06-23 Beyondspring Pharmaceuticals, Inc. Compositions and methods for generating anti-tumor immune response
KR102375269B1 (ko) * 2021-01-27 2022-03-17 한미약품 주식회사 단백질 액상 제제 및 이의 제조방법
JP2024513505A (ja) 2021-04-09 2024-03-25 ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド 腫瘍を治療するための組成物及び方法
CN113456643B (zh) * 2021-08-11 2022-04-01 遵义医科大学 一种含普那布林的药物组合及其应用
CN117860672A (zh) 2022-10-11 2024-04-12 大连万春布林医药有限公司 一种普那布林胶束组合物及其制备方法
FI131561B1 (en) * 2023-12-28 2025-06-30 Faron Pharmaceuticals Oy CLEVER-1 INHIBITOR TO PROMOTE HEMATOLOGICAL RECOVERY WHEN USING CHEMOTHERAPY

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012515222A (ja) * 2009-01-16 2012-07-05 テバ ファーマシューティカル インダストリーズ リミテッド 組換えヒトアルブミン−ヒト顆粒球コロニー刺激因子融合タンパク質の安定な製剤
RU2662298C2 (ru) * 2013-10-11 2018-07-25 Бьёндспринг Инк. Лечение рака комбинацией плинабулина и таксана
AU2017278245B2 (en) * 2016-06-06 2022-09-15 Beyondspring Pharmaceuticals, Inc. Composition and method for reducing neutropenia
KR20190109479A (ko) * 2017-02-01 2019-09-25 비욘드스프링 파마수티컬스, 인코포레이티드. 호중구감소증의 감소 방법

Also Published As

Publication number Publication date
JP2024015120A (ja) 2024-02-01
AU2019216305A1 (en) 2020-08-27
AU2019216305B2 (en) 2024-11-21
SG11202006990TA (en) 2020-08-28
CA3089391A1 (en) 2019-08-08
US20210030843A1 (en) 2021-02-04
NZ766454A (en) 2024-02-23
RU2020126600A (ru) 2022-03-01
JP2021512121A (ja) 2021-05-13
KR20200116477A (ko) 2020-10-12
WO2019152530A1 (en) 2019-08-08
EP3746076A1 (en) 2020-12-09
BR112020015758A2 (pt) 2020-12-08
CN112105363A (zh) 2020-12-18
EP3746076A4 (en) 2021-12-22

Similar Documents

Publication Publication Date Title
IL276197A (en) Composition and method for reducing the neutrophil deficiency caused by chemotherapy through the administration of palinabolin and G-CSF factor
IL283177A (en) Preparations and methods for delivering a specific charge to a cell
SG11202106144VA (en) Compositions for the delivery of therapeutic agents and methods of use and making thereof
IL322464A (en) Methods and compositions for administering therapeutic protein
EP3813853A4 (en) DELIVERY COMPOSITIONS AND METHODS OF USE
IL276148A (en) A preparation and method for reducing platelet count through the administration of palinabolin
EP3946547A4 (en) DEVICES AND METHODS FOR DELIVERING PHARMACEUTICAL COMPOSITIONS
PL3402480T4 (pl) Kompozycje i sposoby dożylnego podawania 2-bromo-1-(3,3-dinitroazetydyn-1-ylo)etanonu
EP3714887A4 (en) PHARMACEUTICAL COMPOSITION FOR TOPICAL ADMINISTRATION AND RELATED PREPARATION PROCESS
IL281073A (en) History of imidazopyridine and pharmaceutical preparations containing them
EP3838265A4 (en) INJECTABLE PHARMACEUTICAL COMPOSITION AND METHOD FOR PREPARATION
EP3749370C0 (de) Pharmazeutische formulierungen, verfahren zum herstellen einer pharmazeutischen formulierung sowie ein arzneimittel umfassend eine solche
IL279877A (en) Ibusidanib forms and pharmaceutical preparations
PL4048230T3 (pl) Doustne kompozycje gliptiny i sposób ich wytwarzania
EP3982942A4 (en) DRUG DELIVERY METHODS AND COMPOSITIONS
EP3813842A4 (en) PHARMACEUTICAL COMPOSITION AND MANUFACTURING PROCESS THEREOF
EP3824888A4 (en) PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION COMPRISING FAB I INHIBITORS AND METHOD FOR PREPARING IT
IL287137A (en) Preparations and methods for administration of healing substances
IL284132A (en) A pharmaceutical compound, a method for its preparation and its use as a medicinal substance
ZA202104261B (en) Combination pharmaceutical compositions and methods thereof
IL281080A (en) Preparations containing a compound containing selenite and a pharmaceutically acceptable acid for the treatment of human papillomavirus infection
EP3781194A4 (en) COMPOSITIONS AND METHODS FOR SELECTIVE DELIVERY OF THERAPEUTIC AND IMAGING AGENTS
SG11202101547WA (en) Pharmaceutical composition for oral administration
HK40067950B (en) Devices and methods for delivering pharmaceutical compositions
HK40047072A (en) Compositions and methods for the selective delivery of therapeutic and imaging agents